You are now leaving Neulasta.com

The sponsor of this site is not responsible for the content on the site you are about to enter.

CANCEL CONTINUE

You are going to a website that contains clinical information and was created specifically for healthcare professionals. If you are not a healthcare professional, and would like to return to the consumer site, please click CANCEL.

CANCEL CONTINUE

Tell A Friend

To send a link from Neulasta.com to someone you know, please complete the form.

All fields must be completed.

Please correct the errors below and try again.
Sending Email
We will not use the information you have provided for any purpose other than to send this email.

Thank You!

The address of this page
has been forwarded successfully.

CLICK TO CONTINUE

Important Safety Information

Who should not take Neulasta®?

Do not take Neulasta® if you have had a serious allergic reaction to pegfilgrastim (Neulasta®) or to filgrastim (Neupogen®).

What should I tell my health care provider before taking Neulasta®? Tell your healthcare provider if you:

  • Have sickle cell trait or sickle cell disease
  • Have had severe skin reactions to acrylic adhesives
  • Are allergic to latex
  • Have any other medical problems
  • Are pregnant or plan to become pregnant
  • Are breastfeeding or plan to breastfeed

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are possible serious side effects of Neulasta®?

  • Spleen Rupture. Your spleen may become enlarged and can rupture while taking Neulasta. A ruptured spleen can cause death. Call your doctor right away if you have pain in the left upper stomach area or left shoulder tip area. This pain could mean your spleen is enlarged or ruptured.
  • A serious lung problem called acute respiratory distress syndrome (ARDS). Call your health care provider or get emergency medical help right away if you get any of these symptoms of ARDS: fever, shortness of breath, trouble breathing, or a fast rate of breathing.
  • Serious Allergic Reactions. Get emergency medical help right away if you get any of these symptoms of a serious allergic reaction with Neulasta: shortness of breath, wheezing, dizziness, swelling around the mouth or eyes, fast pulse, sweating, and hives. If you have an allergic reaction during the delivery of Neulasta, remove the On-body Injector for Neulasta by grabbing the edge of the adhesive pad and peeling off the On-body Injector for Neulasta. Get emergency medical help right away.
  • Sickle Cell Crises. Severe sickle cell crises, and sometimes death, can happen in people with sickle cell trait or disease who receive filgrastim, a medicine similar to Neulasta.

The most common side effect of Neulasta is pain in the bones and in your arms and legs.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Neulasta. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

For more information about Neulasta, talk with your healthcare provider or pharmacist; go to www.neulasta.com, or call 1-844-696-3852 (1-844-MYNEULASTA).

Please see the Neulasta Patient Information for additional information.

Indication

Neulasta® (pegfilgrastim) is a prescription medication used to help reduce the chance of infection due to a low white blood cell count, in people with certain types of cancer (non-myeloid), who receive anti-cancer medicines (chemotherapy) that can cause fever and low blood cell count.

It is not known if Neulasta is safe and effective in children.

Clinical Results for Neulasta®

In clinical trials, the most common side effect of Neulasta is pain in the bones and in your arms and legs.

Key study results

Neulasta® was shown to help reduce the risk of infection with fever (sometimes called febrile neutropenia or neutropenic fever) through strong chemo treatment.1-4

In a key study of 928 breast cancer patients who received up to 4 cycles of strong chemotherapy, one group of patients received Neulasta® (the study group), while the other group did not receive Neulasta® (the placebo group).1,4

The study results showed a1,4:

  • 94% reduction in the cases of febrile neutropenia (low white blood cell count with fever, a sign of infection) in the group of patients receiving Neulasta®
    • 17% of patients not treated with Neulasta®got an infection vs 1% of Neulasta® patients
  • 93% reduction in the number of patients hospitalized for febrile neutropenia and associated infections
    • 14% of patients not treated with Neulasta® were hospitalized vs 1% of Neulasta®
  • 80% reduction in intravenous (IV) anti-infective medication use
    • 10% of patients not treated with Neulasta® needed IV anti-infective medication vs 2% of Neulasta® patients1
  • The most common side effect experienced with Neulasta® was aching in the bones or muscles

Neulasta® reduced infection risk by 94% in patients
taking strong chemotherapy when used every cycle1,4

TALK WITH YOUR DOCTOR BEFORE STARTING STRONG CHEMO

Ask your doctor if you may be at risk for infection

PATIENT STORIES

Real patients with cancer share their stories

References

  1. Neulasta® (pegfilgrastim) Prescribing Information, Amgen.
  2. Green M, Koelbl H, Baselga J, et al. Ann Oncol. 2003;14:29-35.
  3. Holmes FA, O’Shaughnessy JA, Vukelja S, et al. J Clin Oncol. 2002;20:727-731.
  4. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. J Clin Oncol. 2005;23:1178-1184.